|
|||||
|
|
Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis |
|
| Authors: | Niklas Bergvall Raquel Lahoz Tracy Reynolds Jonathan R. Korn |
| Affiliation: | 1. Novartis Pharma AGBaselSwitzerland;2. IMS HealthWaltham, MAUSA |
| Abstract: | |
| Keywords: | Administrative claims Effectiveness Fingolimod Healthcare resource Multiple sclerosis Natalizumab Relapses |